27387-90-2

Basic information

• Product Name: 3-(3,5-Dichlorophenyl)-1-methylhydantoin
• Synonyms: 3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-IMIDAZOLIDINEDIONE;3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-IMIDAZOLIDINONE;3-(3,5-DICHLOROPHENYL)-1-METHYL HYDANTOIN;3-(3,5-Dichlorophenyl)Hydantoin;3-(3,5-DICHLOROPHENYL)-1-METHYLHYDANTOIN(3-(3,5-DICHLOROPHENYL)-1-METHYL-2,4-IMIDAZOLIDINEDIONE)
• CAS NO: 27387-90-2
• Molecular Formula: C₁₀H₈Cl₂N₂O₂
• Molecular Weight: 259.09
• Mol File: 27387-90-2.mol

Chemical Properties

• Melting Point: 202-203.5 °C(Solv: ethanol (64-17-5))
• Boiling Point: 377.293 °C at 760 mmHg
• Flash Point: 181.98 °C
• Appearance: /
• Density: 1.507 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.617
• PKA: -1.90±0.20(Predicted)
• CAS DataBase Reference: 3-(3,5-Dichlorophenyl)-1-methylhydantoin(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,5-Dichlorophenyl)-1-methylhydantoin(27387-90-2)
• EPA Substance Registry System: 3-(3,5-Dichlorophenyl)-1-methylhydantoin(27387-90-2)

Safety Data

• Hazardous Substances Data: 27387-90-2(Hazardous Substances Data)

Usage

Uses

Used in Veterinary Medicine:
3-(3,5-Dichlorophenyl)-1-methylhydantoin is used as an antiprotozoal agent for the prevention and treatment of coccidiosis in animals. It is particularly effective in controlling the disease in poultry and other livestock due to its ability to inhibit the growth and spread of coccidian parasites.
Used in Poultry and Livestock Industries:
3-(3,5-Dichlorophenyl)-1-methylhydantoin is used as a feed additive in the poultry and livestock industries to manage coccidiosis. Its administration helps in maintaining the health of the animals and improving their productivity by preventing the negative impacts of the parasitic infection.

InChI:InChI=1/C10H8Cl2N2O2/c1-13-5-9(15)14(10(13)16)8-3-6(11)2-7(12)4-8/h2-4H,5H2,1H3

Upstream product

• 52605-49-9 sarcosine ethyl ester hydrochloride 
• 34893-92-0 3,4-dichlorophenyl isocyanate 
• 637-96-7 sarcosine hydrochloride 
• 13200-60-7 Sarcosine ethyl ester 

Downstream Products

• 509083-47-0 (E)-5-(4-bromobenzylidene)-3-(3,5-dichlorophenyl)-1-methylimidazolidine-2,4-dione 
• 882004-93-5 C₄₁H₃₂Cl₄N₈O₄ 
• 509083-74-3 4-((5R,9S)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro-[4.4]nonan-9-yl)benzonitrile 
• 509083-73-2 4-((5S,9R)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro-[4.4]nonan-9-yl)benzonitrile 
• 509083-46-9 (E)-4-((1-(3,5-dichlorophenyl)-3-methyl-2,5-dioxoimidazolidin-4-ylidene)methyl)benzonitrile 

Relevant articles and documents

Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5- dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl] -3-thiophenecarboxylic Acid (BMS-587101) - A small molecule antagonist of leukocyte function associated antigen-1

LFA-1 (leukocyte function-associated antigen-1), is a member of the β2-integrin family and is expressed on all leukocytes. This letter describes the discovery and preliminary SAR of spirocyclic hydantoin based LFA-1 antagonists that culminated in the iden

Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): Structure-activity relationships leading to the identification of 6-((5 S,9 R)-9-(4-Cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7- triazaspiro[4.4]nonan-7-yl)nico

Leukocyte function-associated antigen-1 (LFA-1), also known as CD11a/CD18 or αLβ2, belongs to the β2 integrin subfamily and is constitutively expressed on all leukocytes. The major ligands of LFA-1 include three intercellu

Kilogram synthesis of a LFA-1/ICAM inhibitor

The process development and the kilogram-scale synthesis of BMS-587101 (1) are described. The synthesis features a [3 + 2] azomethine ylide cycloaddition to efficiently build the spirocyclic core in a diastereoselective fashion followed by a classical res

CRYSTALLINE FORMS OF6- [(5S, 9R) -9- (4-CYANOPHENYL) -3-(3, 5-DICHLOROPHENYL) -1-METHYL-2, 4-DIOXO-1, 3, 7-TRIAZASPIRO [4.4] NON-7-YL] NICOTINIC

The invention provides crystalline forms of 6-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl]nicotinic acid, its pharmaceutically acceptable salts, or solvates, thereof Further, a process is provided fo

Crystalline forms and process for preparing spiro-hydantoin compounds

A process is provided for preparing spiro-hydantoin compounds of the formula II wherein Z is N or CR4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A2 is a linker, G′ is a linker; Q is a link

Spiro-hydantoin compounds useful as anti-inflammatory agents

Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR4b; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R2 R4a, R4b, and R4c are as defined in the specification.